Both COVID-19 and vaccinations against it have been related to immune cutaneous manifestations. Here, we present a case of childhood vitiligo, developed after a COVID-19 infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518528 | PMC |
| http://dx.doi.org/10.4081/dr.2023.9547 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Variable clinical presentation of hypomorphic DCLRE1C deficiency from childhood to adulthood.
Pediatr Allergy Immunol
October 2024
Division of Pediatric Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
Article Synopsis
- The study focuses on long-term follow-up of 18 pediatric and adult patients with hypomorphic DCLRE1C mutations diagnosed with leaky severe combined immunodeficiency (SCID).
- Common clinical manifestations included recurrent infections, skin issues, autoimmune diseases, and malignancy, with a significant number of patients showing low immunoglobulin levels and T/B-cell lymphopenia.
- Findings suggested a dominant Th1 immune response, with elevated IFN-γ and T cells contributing to chronic inflammation and autoimmunity, emphasizing the need for ongoing patient monitoring post-hematopoietic stem cell transplantation (HSCT).
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
Emerging therapies and innovations in vitiligo management: a comprehensive review.
J Immunoassay Immunochem
January 2025
Department of Pharmaceutics, SCSSS's Sitabai Thite College of Pharmacy, Shirur, India.
Article Synopsis
- * In India, about 1% of the population is affected, especially in northern regions, with connections to other autoimmune diseases.
- * Recent advancements in treatment include new therapies like targeted molecular treatments, improved drug delivery systems, and novel clinical trials, while ongoing research focuses on genetic and environmental factors influencing the disease.
Similar Seasonality in Childhood-Onset, Pediatric, and Adulthood-Onset Vitiligo: A Common Data Model Analysis of 16 Real-World Databases.
Ann Dermatol
October 2024
Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
Clinico-Epidemiological Profile of Childhood Vitiligo.
Indian Dermatol Online J
May 2024
Department of Pediatric Dermatology, Cutis Academy of Cutaneous Sciences, Bengaluru, Karnataka, India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!